tetano
Editor, Senior Moderator
J Korean Med Sci
. 2021 May 31;36(21):e157.
doi: 10.3346/jkms.2021.36.e157.
Antibody Responses One Year after Mild SARS-CoV-2 Infection
Pyoeng Gyun Choe[SUP] #[/SUP][SUP] 1 [/SUP], Kye Hyung Kim[SUP] #[/SUP][SUP] 2 [/SUP], Chang Kyung Kang[SUP] 1 [/SUP], Hyeon Jeong Suh[SUP] 1 [/SUP], EunKyo Kang[SUP] 3 [/SUP], Sun Young Lee[SUP] 3 [/SUP], Nam Joong Kim[SUP] 1 [/SUP], Jongyoun Yi[SUP] 4 [/SUP], Wan Beom Park[SUP] 5 [/SUP], Myoung Don Oh[SUP] 1 [/SUP]
Affiliations
Abstract
Understanding the long-term kinetics of antibodies in coronavirus disease 2019 (COVID-19) is essential in interpreting serosurvey data. We investigated the antibody response one year after infection in 52 mildly symptomatic patients with severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection, using three commercial immunoassays and a surrogate virus neutralization test (sVNT) kit. Anti-N pan-immunoglobulin (Ig), anti-S IgG, and anti-S1 IgG were detected in 43 (82.7%), 44 (84.6%), and 30 (57.7%), respectively. In 49 (94.2%), the antibody could be detected by either anti-N pan-Ig or anti-S IgG assay. In the sVNT, 30 (57.7%) had positive neutralizing activity. Despite waning immunity, SARS-CoV-2 antibodies can be detected up to one year after infection, even in mild COVID-19 patients.
Keywords: Antibody; COVID-19; ECLIA; ELISA; SARS-CoV-2.
. 2021 May 31;36(21):e157.
doi: 10.3346/jkms.2021.36.e157.
Antibody Responses One Year after Mild SARS-CoV-2 Infection
Pyoeng Gyun Choe[SUP] #[/SUP][SUP] 1 [/SUP], Kye Hyung Kim[SUP] #[/SUP][SUP] 2 [/SUP], Chang Kyung Kang[SUP] 1 [/SUP], Hyeon Jeong Suh[SUP] 1 [/SUP], EunKyo Kang[SUP] 3 [/SUP], Sun Young Lee[SUP] 3 [/SUP], Nam Joong Kim[SUP] 1 [/SUP], Jongyoun Yi[SUP] 4 [/SUP], Wan Beom Park[SUP] 5 [/SUP], Myoung Don Oh[SUP] 1 [/SUP]
Affiliations
- PMID: 34060263
- PMCID: PMC8167408
- DOI: 10.3346/jkms.2021.36.e157
Abstract
Understanding the long-term kinetics of antibodies in coronavirus disease 2019 (COVID-19) is essential in interpreting serosurvey data. We investigated the antibody response one year after infection in 52 mildly symptomatic patients with severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection, using three commercial immunoassays and a surrogate virus neutralization test (sVNT) kit. Anti-N pan-immunoglobulin (Ig), anti-S IgG, and anti-S1 IgG were detected in 43 (82.7%), 44 (84.6%), and 30 (57.7%), respectively. In 49 (94.2%), the antibody could be detected by either anti-N pan-Ig or anti-S IgG assay. In the sVNT, 30 (57.7%) had positive neutralizing activity. Despite waning immunity, SARS-CoV-2 antibodies can be detected up to one year after infection, even in mild COVID-19 patients.
Keywords: Antibody; COVID-19; ECLIA; ELISA; SARS-CoV-2.